However, a clear correlation between the predicted severity of a mutation and presence of functional Meibomian glands in affected animals seems difficult. Based on SIFT scoring (in the public domain,
http://sift.jcvi.org/), an online tool to predict the severity of mutations, two
Gsdma3 mutations, Rco2 (p.Leu343Pro) and RIKEN00745/+ (p.Tyr442*), incorporate amino acid changes that are predicted to severely influence protein structure and function (with a SIFT score of 0.00) but show intact Meibomian glands in combination with a severe skin phenotype.
3,8 While the RIKEN00745/+ p.Tyr442* mutation
3 only affects the last few amino acids of the C-terminus, the Rco2 p.Leu343Pro mutation
8 is located in a highly conserved stretch of amino acids in helix α8 where any kind of change is predicted to disrupt protein structure according to SIFT scoring. The exchange of leucine to proline should effectively break helix α8 in this mutation. Despite these putatively disruptive changes, Meibomian glands remain functional in Rco2 (age: 2 months
8) and RIKEN00745/+ (age: 10 months
3) mice while sebaceous glands are absent from the skin of these animals. In contrast, three other
Gsdma3 mutations (Ae, Bsk, and M2Btlr) show changes in the adjacent tyrosine residue (Ae: p.Tyr344His,
4 Bsk,
5 and M2Btlr: p.Tyr344Cys). These amino acid changes are predicted to only mildly influence protein structure (SIFT scores are 0.13 and 0.18, respectively), yet these mice show a corneal phenotype. Meibomian gland morphology was not described for these three mouse lines. However, tyrosine 344 is predicted to directly contact amino acids located in the N-terminal domain of Gasdermin A3,
21 which could explain the high impact of mutations in this particular residue compared to the milder phenotype observed in leucine 343 mutants.